289 related articles for article (PubMed ID: 32479865)
1. Lack of antiviral activity of darunavir against SARS-CoV-2.
De Meyer S; Bojkova D; Cinatl J; Van Damme E; Buyck C; Van Loock M; Woodfall B; Ciesek S
Int J Infect Dis; 2020 Aug; 97():7-10. PubMed ID: 32479865
[TBL] [Abstract][Full Text] [Related]
2. Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection.
Kim EJ; Choi SH; Park JS; Kwon YS; Lee J; Kim Y; Lee SY; Choi EY
Yonsei Med J; 2020 Sep; 61(9):826-830. PubMed ID: 32882767
[TBL] [Abstract][Full Text] [Related]
3. Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6.
Cojutti PG; Londero A; Della Siega P; Givone F; Fabris M; Biasizzo J; Tascini C; Pea F
Clin Pharmacokinet; 2020 Oct; 59(10):1251-1260. PubMed ID: 32856282
[TBL] [Abstract][Full Text] [Related]
4. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
[TBL] [Abstract][Full Text] [Related]
5. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
6. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
Sun D
AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
[TBL] [Abstract][Full Text] [Related]
8. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
9. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
10. Repurposing old drugs as antiviral agents for coronaviruses.
Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
Softic L; Brillet R; Berry F; Ahnou N; Nevers Q; Morin-Dewaele M; Hamadat S; Bruscella P; Fourati S; Pawlotsky JM; Ahmed-Belkacem A
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32376613
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
13. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
[TBL] [Abstract][Full Text] [Related]
14. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
[TBL] [Abstract][Full Text] [Related]
15. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study.
Lian N; Xie H; Lin S; Huang J; Zhao J; Lin Q
Clin Microbiol Infect; 2020 Jul; 26(7):917-921. PubMed ID: 32344167
[TBL] [Abstract][Full Text] [Related]
16. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
17. Targeting Proteases for Treating COVID-19.
Luan B; Huynh T; Cheng X; Lan G; Wang HR
J Proteome Res; 2020 Nov; 19(11):4316-4326. PubMed ID: 33090793
[TBL] [Abstract][Full Text] [Related]
18. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.
Polansky H; Lori G
J Evid Based Integr Med; 2020; 25():2515690X20932523. PubMed ID: 32551855
[TBL] [Abstract][Full Text] [Related]
19. [SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].
Ladoux A; Azoulay S; Dani C
Med Sci (Paris); 2020; 36(6-7):555-558. PubMed ID: 32558640
[No Abstract] [Full Text] [Related]
20. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.
Härter G; Spinner CD; Roider J; Bickel M; Krznaric I; Grunwald S; Schabaz F; Gillor D; Postel N; Mueller MC; Müller M; Römer K; Schewe K; Hoffmann C
Infection; 2020 Oct; 48(5):681-686. PubMed ID: 32394344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]